EFPIA states AI rules must “enable not hinder” pharma R&D
Drug Discovery World
APRIL 24, 2024
The Federation added: “It is critical that the regulatory frameworks governing the use of AI in research, development and manufacture must be fit-for-purpose, risk-based, non-duplicative, globally aligned, and adequately tailored.
Let's personalize your content